Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
- 1 November 2006
- journal article
- review article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 65 (suppl 3) , iii2-iii15
- https://doi.org/10.1136/ard.2006.061937
Abstract
The perspective of this consensus is from the treating physician’s point of view.Keywords
This publication has 201 references indexed in Scilit:
- Familial Mediterranean fever responds well to infliximab: single case experienceClinical Rheumatology, 2005
- Psoriasis—recent advances in understanding its pathogenesis and treatmentJournal of the American Academy of Dermatology, 2005
- Infliximab treatment for refractory Kawasaki syndromeThe Journal of Pediatrics, 2005
- Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndromeThe Journal of Pediatrics, 2004
- Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled studyJournal of Hepatology, 2004
- Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: Report of 3 casesJournal of the American Academy of Dermatology, 2004
- How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACHInternational Journal of Cardiology, 2002
- Remission of Behçet's syndrome with TNFα blocking treatmentAnnals of the Rheumatic Diseases, 2002
- InfliximabDrugs, 2000
- EtanerceptDrugs, 1999